{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:25:59Z","timestamp":1769743559358,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["AIRC IG16833"],"award-info":[{"award-number":["AIRC IG16833"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,29]]},"DOI":"10.1093\/carcin\/bgy177","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T12:07:50Z","timestamp":1544443670000},"page":"303-312","source":"Crossref","is-referenced-by-count":33,"title":["Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma"],"prefix":"10.1093","volume":"40","author":[{"given":"Laura","family":"Carminati","sequence":"first","affiliation":[{"name":"Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Pinessi","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Borsotti","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Minoli","sequence":"additional","affiliation":[{"name":"Mouse and Animal Pathology Lab, Fondazione Filarete, Milan, Italy"},{"name":"Department of Veterinary Pathology, University of Milan, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Giavazzi","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8784-1360","authenticated-orcid":false,"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorina","family":"Belotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-5001","authenticated-orcid":false,"given":"Giulia","family":"Taraboletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,12,24]]},"reference":[{"key":"2019042909133031700_CIT0001","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-015-2918-1","article-title":"Unique features of trabectedin mechanism of action","volume":"77","author":"Larsen","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2019042909133031700_CIT0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/fon.13.207","article-title":"Trabectedin mechanism of action: what\u2019s new","volume":"9","author":"D\u2019Incalci","year":"2013","journal-title":"Future Oncol."},{"key":"2019042909133031700_CIT0003","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bjc.2014.149","article-title":"Trabectedin, a drug acting on both cancer cells and the tumour microenvironment","volume":"111","author":"D\u2019Incalci","year":"2014","journal-title":"Br. J. Cancer"},{"key":"2019042909133031700_CIT0004","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","article-title":"Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells","volume":"70","author":"Germano","year":"2010","journal-title":"Cancer Res."},{"key":"2019042909133031700_CIT0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","article-title":"Role of macrophage targeting in the antitumor activity of trabectedin","volume":"23","author":"Germano","year":"2013","journal-title":"Cancer Cell"},{"key":"2019042909133031700_CIT0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ijc.29023","article-title":"Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1","volume":"136","author":"Dossi","year":"2015","journal-title":"Int. J. Cancer"},{"key":"2019042909133031700_CIT0007","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/ng1634","article-title":"The melanocyte differentiation program predisposes to metastasis after neoplastic transformation","volume":"37","author":"Gupta","year":"2005","journal-title":"Nat. Genet."},{"key":"2019042909133031700_CIT0008","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1158\/0008-5472.CAN-06-0731","article-title":"Influence of the microenvironment on melanoma cell fate determination and phenotype","volume":"66","author":"Postovit","year":"2006","journal-title":"Cancer Res."},{"key":"2019042909133031700_CIT0009","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2019042909133031700_CIT0010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-008-0067-y","article-title":"Melanoma and the tumor microenvironment","volume":"10","author":"Villanueva","year":"2008","journal-title":"Curr. Oncol. Rep."},{"key":"2019042909133031700_CIT0011","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/sj.onc.1206457","article-title":"Angiogenesis, lymphangiogenesis, and melanoma metastasis","volume":"22","author":"Streit","year":"2003","journal-title":"Oncogene"},{"key":"2019042909133031700_CIT0012","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.seminoncol.2007.09.009","article-title":"Angiogenesis in melanoma","volume":"34","author":"Mahabeleshwar","year":"2007","journal-title":"Semin. Oncol."},{"key":"2019042909133031700_CIT0013","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/sj.jid.5700827","article-title":"Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft","volume":"127","author":"Gazzaniga","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"2019042909133031700_CIT0014","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2613.2006.00478.x","article-title":"Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity","volume":"87","author":"Hussein","year":"2006","journal-title":"Int. J. Exp. Pathol."},{"key":"2019042909133031700_CIT0015","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1158\/1078-0432.CCR-11-1354","article-title":"Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2019042909133031700_CIT0016","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2019042909133031700_CIT0017","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"key":"2019042909133031700_CIT0018","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.1253735","article-title":"The melanoma revolution: from UV carcinogenesis to a new era in therapeutics","volume":"346","author":"Lo","year":"2014","journal-title":"Science"},{"key":"2019042909133031700_CIT0019","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"2019042909133031700_CIT0020","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"2019042909133031700_CIT0021","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"2019042909133031700_CIT0022","first-page":"1636","article-title":"In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties","volume":"40","author":"Poste","year":"1980","journal-title":"Cancer Res."},{"key":"2019042909133031700_CIT0023","first-page":"587","article-title":"The selection and characterization of an invasive variant of the B16 melanoma","volume":"97","author":"Hart","year":"1979","journal-title":"Am. J. Pathol."},{"key":"2019042909133031700_CIT0024","first-page":"975","article-title":"Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors","volume":"69","author":"Talmadge","year":"1982","journal-title":"J. Natl. Cancer Inst."},{"key":"2019042909133031700_CIT0025","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"2019042909133031700_CIT0026","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1038\/onc.2013.462","article-title":"Mode of action of trabectedin in myxoid liposarcomas","volume":"33","author":"Di Giandomenico","year":"2014","journal-title":"Oncogene"},{"key":"2019042909133031700_CIT0027","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1158\/0008-5472.CAN-04-4037","article-title":"Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production","volume":"65","author":"Allavena","year":"2005","journal-title":"Cancer Res."},{"key":"2019042909133031700_CIT0028","doi-asserted-by":"crossref","first-page":"e1393596","DOI":"10.1080\/2162402X.2017.1393596","article-title":"Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype","volume":"7","author":"Borgoni","year":"2018","journal-title":"Oncoimmunology"},{"key":"2019042909133031700_CIT0029","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/onc.2013.194","article-title":"Melanoma metastasis: new concepts and evolving paradigms","volume":"33","author":"Damsky","year":"2014","journal-title":"Oncogene"},{"key":"2019042909133031700_CIT0030","first-page":"2541","article-title":"Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency","volume":"60","author":"Cameron","year":"2000","journal-title":"Cancer Res."},{"key":"2019042909133031700_CIT0031","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cell.2008.09.043","article-title":"Rac activation and inactivation control plasticity of tumor cell movement","volume":"135","author":"Sanz-Moreno","year":"2008","journal-title":"Cell"},{"key":"2019042909133031700_CIT0032","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.cub.2015.09.054","article-title":"TGF-\u03b2-induced transcription sustains amoeboid melanoma migration and dissemination","volume":"25","author":"Cantelli","year":"2015","journal-title":"Curr. Biol."},{"key":"2019042909133031700_CIT0033","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1038\/sj.bjc.6601431","article-title":"In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects","volume":"89","author":"Simoens","year":"2003","journal-title":"Br. J. Cancer"},{"key":"2019042909133031700_CIT0034","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/ijc.28213","article-title":"Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis\u00ae (PM00104)","volume":"133","author":"Romano","year":"2013","journal-title":"Int. J. Cancer"},{"key":"2019042909133031700_CIT0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4048\/jbc.2015.18.4.329","article-title":"Synergistic effect of trabectedin and olaparib combination regimen in breast cancer cell lines","volume":"18","author":"\u00c1vila-Arroyo","year":"2015","journal-title":"J. Breast Cancer"},{"key":"2019042909133031700_CIT0036","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-14-1688","article-title":"Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents","volume":"21","author":"Amaral","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2019042909133031700_CIT0037","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-017-0451-x","article-title":"Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas","volume":"10","author":"Laroche","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"2019042909133031700_CIT0038","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br. J. Cancer"},{"key":"2019042909133031700_CIT0039","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2019042909133031700_CIT0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet. Oncol."},{"key":"2019042909133031700_CIT0041","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"43","author":"Franklin","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"2019042909133031700_CIT0042","first-page":"1071","article-title":"Cutaneous melanoma: from pathogenesis to therapy (Review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"2019042909133031700_CIT0043","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-16-3186","article-title":"Trabectedin overrides osteosarcoma differentiative block and reprograms the tumor immune environment enabling effective combination with immune checkpoint inhibitors","volume":"23","author":"Ratti","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/40\/2\/303\/28541583\/bgy177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T05:17:02Z","timestamp":1720847822000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/40\/2\/303\/5244098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,24]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,12,24]]},"published-print":{"date-parts":[[2019,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgy177","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2018,12,24]]}}}